Speaker Profile
Evan S. Dellon

Evan S. Dellon MD, MPH

Gastroenterology, Public Health
Chapel Hill, North Carolina, United States of America

Connect with the speaker?

Evan Dellon, MD, MPH, professor of medicine, was recognized as a Top Ten Clinical Research Achievement Awardee for his study titled “Anti-Selig-8 Antibody for Eosinophilic Gastritis and Duodenitis,” which was published in the New England Journal of Medicine last fall. Eosinophilic gastrointestinal disorders are an under-recognized cause of gastrointestinal illness. Increasing in incidence for reasons that are unclear, eosinophilic GI disorders have no FDA-approved therapies. Dellon and his colleagues performed a randomized controlled trial of lirentelimab, an anti-Siglec-8 antibody, in patients with eosinophilic gastritis and duodenitis. This monoclonal antibody depletes eosinophils and inhibits mast cells, which are thought to be critical in the pathogenesis of these diseases.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)